MET and melanoma: Exposure to 0.25 μm crizotinib, an inhibitor of c-MET, after induction of BRN2 expression led to a significant decrease in cellular viability in non-adherent conditions in all three melanoma cell lines examined (MM370, p = 0.0029; MM455, p = 0.02; MM603, p = 0.0039; Fig. 6a–c).